Choosing a First Biologic Around the Eyes, Not Just the Spine
Her spine disease alone would barely need a biologic yet. Three episodes of anterior uveitis in eighteen months are the real reason she's here — and the two TNF inhibitors that look interchangeable for her joints have opposite reputations for the eye disease that's actually driving today's visit.
Bridget A. has built a career as a wedding and portrait photographer over the past fifteen years, work that depends on her eyes the way a surgeon's depends on their hands, which is part of why the three episodes of acute anterior uveitis she's had in the last eighteen months feel like a bigger threat to her than the ankylosing spondylitis technically driving them. Her axial disease itself is genuinely mild — BASDAI 3.8, well-controlled functionally with NSAIDs and a home exercise program, not by itself an urgent case for a biologic. The uveitis is a different story: each episode brought days of photophobia and blurred vision severe enough to cancel shoots, treated each time with topical steroids by an ophthalmologist increasingly concerned about the cumulative risk of steroid-related glaucoma and cataracts from repeated courses.
Her rheumatologist's reasoning for reaching for a biologic now, ahead of where her joint disease alone would justify it, is built entirely around the eyes rather than the spine — which changes which TNF inhibitor is actually the right first choice. Etanercept and adalimumab are often treated as interchangeable TNF inhibitors for axial disease, roughly comparable on spine outcomes in most patients. For uveitis specifically, they are not comparable at all: Zhao and colleagues, pooling eighteen studies and 11,529 AS patients, found adalimumab cut new-onset uveitis risk to roughly a third of etanercept's and recurrent uveitis to about seventy percent of it, and a nationwide population-based cohort found etanercept carried a higher incidence of acute anterior uveitis than adalimumab whether or not a patient had a prior uveitis history. The structural explanation is not that etanercept lacks an Fc region — it has one, an IgG1 Fc, which is what the p75 receptor domain is fused to. It is that etanercept is a soluble decoy receptor rather than an anti-TNF antibody: it neutralizes circulating TNF but engages membrane-bound TNF far less durably, and that difference tracks with its long-observed weakness in granulomatous and ocular inflammation even where it controls the joints perfectly well.
Her most recent uveitis episode, six weeks ago, left a faint residual synechia her ophthalmologist is still monitoring, a small but real structural reminder that each flare has carried some risk of leaving something behind rather than resolving completely. Her calendar has three weddings booked in the next two months, which sharpens the timeline but does not actually decide anything. What decides it is narrower and worth stating exactly: nothing in the comparative data distinguishes these two drugs on her spine, and the whole difference between them sits in the one organ her axial disease was never going to threaten.
The joint drug and the eye drug aren't the same question
Her spine disease alone wouldn't put a biologic on the table yet — her eyes are why we're here. That changes which TNF inhibitor is right. Zhao's network meta-analysis across more than eleven thousand AS patients found adalimumab significantly reduced new-onset uveitis risk compared with etanercept, and a separate large cohort found etanercept actually increased both new and recurrent uveitis risk relative to adalimumab. For her specifically, adalimumab isn't just "also reasonable" — it's the evidence-matched choice for the actual problem in front of us.
I want to name plainly what's actually happening here: this is an ophthalmologic decision wearing a rheumatology visit. She's had three episodes in eighteen months with real cumulative topical- steroid exposure and early glaucoma-risk changes I'm already tracking. I agree with the drug choice, but I'd want this documented and coordinated as a joint decision between our two specialties, not a routine axSpA biologic start that happens to also help her eyes.
I'd also push to define what "success" means for her specifically — zero further uveitis episodes at six and twelve months, not just improved BASDAI, since her spine was never the urgent problem to begin with.
Both fair, and I'd widen the drug conversation by one option before we finalize it. Adalimumab isn't the only true monoclonal antibody with real uveitis-specific data — infliximab has its own strong, independently demonstrated efficacy for uveitis, sharing the same structural feature (a true anti-TNF antibody binding membrane-bound TNF, not a decoy receptor) that etanercept's design does not reproduce. Given she'd need infusion access rather than a subcutaneous injection, and given adalimumab's data is at least as strong for her specific situation, I'd still land on adalimumab today — but I wanted the full monoclonal field on the table rather than treating this as a two-drug comparison when a third genuinely belongs in it.
Agreed: start adalimumab, with explicit co-management between rheumatology and ophthalmology and a defined success measure of zero uveitis recurrences at 6 and 12 months, tracked alongside routine BASDAI monitoring.
Not agreed: whether infliximab should have been presented to Bridget as an equally-weighted option rather than a secondary alternative. The clinical pharmacologist would have preferred letting her choose between the two monoclonal antibodies directly once both were named; the rheumatologist and ophthalmologist judged adalimumab's subcutaneous convenience decisive enough, given comparably strong efficacy data, that presenting infliximab as fully equal risked complicating the decision without a real corresponding benefit to her.